Cellectis S.A.
EPA:ALCLS.PA
Overview | Financials
Company Name | Cellectis S.A. |
Symbol | ALCLS.PA |
Currency | EUR |
Price | 1.71 |
Market Cap | 123,280,056 |
Dividend Yield | 0% |
52-week-range | 1.634 - 3.44 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Andre Choulika Ph.D. |
Website | https://www.cellectis.com |
An error occurred while fetching data.
About Cellectis S.A.
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies,
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD